Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
Rhea-AI Summary
Syndax (Nasdaq: SNDX) announced that CEO Michael A. Metzger will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 11:15 a.m. ET.
A live webcast will be available in the company’s Investor section at www.syndax.com, and a replay will be posted for a limited time.
Positive
- None.
Negative
- None.
News Market Reaction – SNDX
In the Dec 1 session, SNDX declined 3.53%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2025-12-08 | Clinical data update | Positive | -1.7% | Multiple positive Revuforj data sets presented across acute leukemia settings. |
| 2025-12-03 | Inducement grants | Neutral | +0.2% | New hire inducement stock options under 2023 Inducement Plan. |
| 2025-12-01 | Conference participation | Neutral | -3.5% | CEO scheduled for Evercore Healthcare Conference fireside chat webcast. |
| 2025-11-05 | Inducement grants | Neutral | -2.7% | Equity awards to four new employees under inducement plan. |
| 2025-11-03 | Earnings and update | Positive | +0.4% | 3Q25 results with Revuforj FDA approval and growing prescriptions. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Price usually aligns with news tone; one notable divergence followed highly positive ASH 2025 clinical data.
Over recent months, Syndax reported 3Q25 financials with Revuforj FDA approval and solid revenue, multiple inducement option grants, and strong Revuforj data at ASH 2025. The company also announced this Evercore conference fireside chat with the CEO. Price reactions were generally modest, with most events showing aligned moves, while the robust ASH data event saw a slight negative reaction, highlighting some disconnect between strong clinical updates and short-term trading.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. ET.
A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
